The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia.
Bezafibrate was given to 23 hypertriglyceridemic but otherwise healthy middle-aged men in a double-blind, cross-over study to evaluate its effect on the components of the fibrinolytic system as well as on ATIII, FVIIIR: Ag, FVIII: C and platelet aggregation. Fibrinogen dropped markedly (P less than 0.05) and there was a small but significant fall of ATIII. The second wave of platelet aggregation was found much less frequently than in controls (P less than 0.001). Bezafibrate seemed to decrease the rate of formation of the first wave platelet aggregation.
D000328:Adult; D001629:Bezafibrate / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D014280:Triglycerides / Q000097:blood*
D014280:Triglycerides; D001629:Bezafibrate